Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis, Inc. (NASDAQ: NUWE) announced on May 19, 2021, that its independent directors approved eight equity awards as an inducement for new employment, aligning with NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase 6,227 shares at an exercise price of $3.63, which equals the stock's closing price on the grant date. These options will vest over four years and have a ten-year term. Nuwellis is focused on innovating medical devices for fluid overload treatment through its Aquadex SmartFlow system.
Nuwellis reported promising results for its Aquadex FlexFlow system in treating acutely decompensated heart failure (ADHF) patients. A study presented at the 2021 American College of Cardiology conference involved 30 patients, where 83% showed clinical symptom improvement. The mean fluid removal was 9.40L, with significant reductions in heart failure-related readmissions (p=0.017 at 60 days). These findings align with prior trials, affirming Aquadex's effectiveness without adverse renal impact. The company emphasizes its commitment to addressing heart failure challenges through innovative ultrafiltration therapy.
Nuwellis, Inc. (Nasdaq: NUWE) has expanded the availability of its Aquadex SmartFlow® System to Driscoll Children’s Hospital in Corpus Christi, Texas, aimed at pediatric patients experiencing fluid overload. This system allows for precise fluid removal using only 35 mL of blood, making it particularly advantageous for smaller patients. The technology is clinically proven for children weighing 20 kg or more, helping alleviate complications from conditions like heart and kidney failure. CEO Nestor Jaramillo emphasized their commitment to enhancing access to vital therapies.
Nuwellis, Inc. (Nasdaq: NUWE) reported its first-quarter results for 2021, showing revenue of $1.9 million, an 18% increase year-over-year. The company completed a rebranding from CHF Solutions, Inc. on April 27, 2021. Key highlights include increased Aquadex therapy utilization, the enrollment of the first pediatric patient in a clinical registry, and strong endorsements for a Category III CPT code application. Nuwellis ended the quarter with $27.9 million in cash and no debt, despite a net loss of $5.2 million.
Nuwellis, Inc. (NASDAQ:NUWE), formerly known as CHF Solutions, will announce its first quarter 2021 financial results on May 11, 2021, followed by a conference call at 9:00 AM ET. The session will include discussions on financial outcomes and business overview. Investors can access the live webcast through the company's website. Nuwellis specializes in developing medical devices aimed at alleviating fluid overload through innovative solutions, primarily focused on the Aquadex SmartFlow® system.
Summary not available.